dc.contributor.author | Pentheroudakis, George | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Pentheroudakis, George | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:54:29Z | |
dc.date.available | 2018-06-22T09:54:29Z | |
dc.date.issued | 2006 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42371 | |
dc.description.abstract | Cancer of unknown primary site (CUP) ranks as the fourth most common cause of cancer deaths. Regression of the primary, early development of systemic metastases and resistance to therapy are hallmarks of this heterogeneous clinical entity. Targeted therapy offers promise for improvement of outcome of such patients, but it is currently hindered by lack of known molecular targets on which tumours are dependent for growth. In this review, we present the gene and protein profiling studies done on expression of oncogenes, tumour-suppressor genes and angiogenesis effectors and discuss the therapeutic potential of developed targeted agents. Existing data show occasional overexpression of Ras, BCL2 oncoproteins, absence of active EGFR/c-KIT/PDGFR signalling, uncommon presence of tumour-suppressor gene mutations and highly active angiogenesis in CUP. High-throughput multi-gene, multi-protein platforms offer promise for unravelling the complex molecular pathophysiology of CUP, for identification of targets suitable for modulation and ultimately hope for abrogation of its aggressive natural history. © 2006 Elsevier Ltd. All rights reserved. | en |
dc.language.iso | eng | en |
dc.source | Cancer treatment reviews | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Cisplatin | en |
dc.subject | Human | en |
dc.subject | Neoplasms | en |
dc.subject | Humans | en |
dc.subject | Breast cancer | en |
dc.subject | Drug response | en |
dc.subject | Clinical trial | en |
dc.subject | Antineoplastic activity | en |
dc.subject | Treatment outcome | en |
dc.subject | Review | en |
dc.subject | Erlotinib | en |
dc.subject | Metastasis | en |
dc.subject | Neoplastic | en |
dc.subject | Cancer mortality | en |
dc.subject | Imatinib | en |
dc.subject | Unindexed drug | en |
dc.subject | Colorectal cancer | en |
dc.subject | Lapatinib | en |
dc.subject | Trastuzumab | en |
dc.subject | Genetic polymorphism | en |
dc.subject | Protein bcl 2 | en |
dc.subject | Protein p53 | en |
dc.subject | Gene expression regulation | en |
dc.subject | Carcinogenesis | en |
dc.subject | Cancer | en |
dc.subject | Gelatinase b | en |
dc.subject | Signal transduction | en |
dc.subject | Tumor vascularization | en |
dc.subject | Cancer therapy | en |
dc.subject | Bevacizumab | en |
dc.subject | Gefitinib | en |
dc.subject | Sorafenib | en |
dc.subject | Sunitinib | en |
dc.subject | Drug treatment failure | en |
dc.subject | Unknown primary | en |
dc.subject | Pathophysiology | en |
dc.subject | Unknown primary | en |
dc.subject | Gene expression profiling | en |
dc.subject | Drug targeting | en |
dc.subject | Gene mutation | en |
dc.subject | Platelet derived growth factor receptor | en |
dc.subject | Stem cell factor receptor | en |
dc.subject | Head and neck cancer | en |
dc.subject | Cetuximab | en |
dc.subject | Vandetanib | en |
dc.subject | Cancer resistance | en |
dc.subject | Epidermal growth factor receptor 2 | en |
dc.subject | Tissue inhibitor of metalloproteinase 1 | en |
dc.subject | Cd34 antigen | en |
dc.subject | Thrombospondin 1 | en |
dc.subject | Ras protein | en |
dc.subject | Oncogenes | en |
dc.subject | Advexin | en |
dc.subject | Antiangiogenic activity | en |
dc.subject | Cyclooxygenase 2 | en |
dc.subject | Lonafarnib | en |
dc.subject | Malignant transformation | en |
dc.subject | Oblimersen | en |
dc.subject | Onyx 015 | en |
dc.subject | Targeted therapy | en |
dc.subject | Thalidomide | en |
dc.subject | Tipifarnib | en |
dc.title | Perspectives for targeted therapies in cancer of unknown primary site | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/j.ctrv.2006.08.004 | |
dc.description.volume | 32 | |
dc.description.issue | 8 | |
dc.description.startingpage | 637 | |
dc.description.endingpage | 644 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Pentheroudakis, George [0000-0002-6632-2462] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-6632-2462 | |